In our previous in vivo study employing a different murine campylobacteriosis model, we found that oral menthol of the same concentration therapeutically given to secondary abiotic IL-10−/− mice from day 2 until day 6 p.i. resulted in an improved clinical outcome [45]. The gene discussed is IL10; the disease is campylobacteriosis.